Eisai Co., Ltd. (ESALF)

57,22 +2,12 (+3,85%) Börsenschluss: 03:59PM EDT

Eisai Co., Ltd.

4-6-10, Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan
81 3 3817 3700
https://www.eisai.co.jp

Sektor(en): Healthcare
Branche: Drug Manufacturers—Specialty & Generic
Vollzeitmitarbeiter: 11.322

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Haruo Naito	CEO, Representative Corp. Officer & Director	906,54k	N/A	1947
Mr. Gary Hendler	Sr. VP & Pres of EMEA Region	731,33k	N/A	1966
Dr. Lynn D. Kramer FAAN, M.D.	VP & Chief Clinical Officer - Alzheimer's Disease and Brain Health	761,8k	N/A	1950
Ms. Yanhui Feng	Sr. VP	815,13k	N/A	1972
Dr. Nadeem Sarwar Ph.D.	Pres	N/A	N/A	N/A
Mr. Tatsuyuki Yasuno	Sr. VP, CFO & Chief IR Officer	N/A	N/A	1968
Mr. Kenta Takahashi	Exec. VP, Gen. Counsel & Intellectual Property Internal Audit	N/A	N/A	1959
Mr. Yosuke Akita	VP, Chief Compliance Officer & Chief Information Security Officer	N/A	N/A	1965
Ms. Sayoko Sasaki	VP of Corp. Communications & ESG	N/A	N/A	1968
Mr. Teruyuki Masaka	VP & Chief HR Officer	N/A	N/A	1978

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Corporate Governance

Eisai Co., Ltd.s ISS Governance QualityScore, Stand 1. März 2023, lautet 1. Die grundlegenden Scores sind Audit: 1, Vorstand: 1, Shareholderrechte: 6, Kompensation: 2.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.